

CURRICULUM VITAE

Name: Andrea Zivi, Dr

Date of Birth: [REDACTED]

Place of Birth: [REDACTED]

Citizenship: Italian

Italian Medical Council registration number: 54379

General Medical Council UK registration number: 7029885

Education:

2004 M.D. Catholic University of Sacred Heart, Rome, Italy (Summa Cum Laude)

2005 M.D. Italian National Board Examination in General Medicine and Surgery

2008 Medical Oncologist, "La Sapienza" University, Rome, Italy (Summa cum Laude)

Postdoctoral Training:

01/Nov/2004 – 31/Oct/2008 Resident, Medical Oncology, "La Sapienza" University, Rome, Italy

Academic Position

From 01/Nov/2013 Honorary Clinical Senior Lecturer
Faculty of Medicine
Department of Surgery & Cancer
Section of Cancer,
Imperial College London
South Kensington Campus
SW7 2AZ, London, UK

From Apr/2019 Professore a contratto
Scuola di Specializzazione di Oncologia
Università degli Studi di Verona
Via S. Francesco, 22
37129 Verona - Italy

Principal work experiences:

from 15/Sep/2019 Consultant
Azienda Ospedaliera Universitaria Integrata di Verona
Piazzale A. Stefani 1
UOC Oncologia
37136 Verona - Italy

01/Oct/2018 – 14/Sep/2019 Locum Consultant
Azienda Ospedaliera Universitaria Integrata di Verona
UOC Oncologia
Piazzale A. Stefani 1
37136, Verona - Italy

08/Aug/2016 – 30/Sep/2018 Consultant
Ospedale dell'Angelo Mestre
UO Oncologia Medica
Via Paccagnella, 11
30121 Mestre (VE), Italy

and

Ospedale SS. Giovanni e Paolo Venezia
UO Oncologia Medica
Castello 6777, 30122 Venezia, Italy

25/Apr/2016 - 06/May/2016	Assistant Physician, Medical Oncologist Istituto Oncologico della Svizzera Italiana (IOSI) Via Ospedale 6500 Bellinzona, CH
07/Jun/2015 – 15/Jun/2016	Locum Consultant Ospedale "Fra' Castoro" UOS Oncologia Via Circonvallazione 1, 37047, San Bonifacio (VR), Italy
04/Jul/2014 - 31/Dec/2014	Locum Consultant Ospedale Centrale di Bolzano Medical Oncology Service Via Lorenz Böhler 5, 39100, Bolzano, Italy
17/Jun/2013 - 31/Jun/2014	Honorary Locum Consultant North West London Hospitals Breast Cancer Service Acton Lane, Park Royal, NW10 7NS, London, UK
17/Jun/2013 – 31/Jun/2014	Locum Consultant Imperial College Healthcare NHS Trust, Breast Cancer Service (CXH) GU Cancer Service and Acute Oncology Service (SMH) Fulham Palace Road, W6 8RF, London, UK
01/Feb/2013 - 16/Jun/2013	Clinical Research Fellow The Royal Marsden Hospital NHS Trust Prostate Targeted Therapy Group Downs Road SM2 5PT, Sutton, Surrey, UK
16/Jun/2012 - 31/Jun/2013	Clinical Research Fellow The Royal Marsden Hospital NHS Trust Drug Development Unit Downs Road SM2 5PT, Sutton, Surrey, UK
05/Jun/2009 - 01/Jun/2011	Clinical Research Fellow Institute of Cancer Research UK The Royal Marsden Hospital NHS Trust Prostate Targeted Therapy Group

Downs Road
SM2 5PT, Sutton, Surrey, UK

- 30/Nov/2008 - 15/Jan/2012 Honorary Clinician
The Royal Marsden Hospital NHS Trust
Drug Development Unit, Prostate Targeted Therapy Group
Sutton, Surrey, UK
- 2005 - 2008 Residency under the supervision of the following Consultants:
- Dr C N Sternberg, San Camillo-Forlanini Hospitals, Rome
Management of in/out patients and experience in all tumor types with particular focus on GU, GI, germ cell, lung tumors. Experience in clinical trials
- Dr F Longo, Policlinico Umberto I, Rome
Management of in/out patients and experience in all tumor types with particular focus on Thoracic, GI and breast tumors and STSs

Grants/Awards:

- 21-27/Jun/2008 AIRC grant to attend ECCO-AACR-ASCO Workshop
"Methods in clinical cancer research"
Flims, Switzerland
- 05-07/Mar/2010 ASCO Merit Award
ASCO - ASTRO - SUO
2010 Genitourinary Cancers Symposium:
Progress in multidisciplinary management
San Francisco, California, USA

ICH-GCP Training

- 30/Jan/2009 GCP training
07/Feb/2011 GCP training
25/Feb/2013 GCP training
04/Dec/2017 GCP training
10/Dec/2019 GCP training

Clinical research activities:

- from 2018 Principal-Investigator for >10 clinical trials (phase 1, 2 e 3 and translational research)
from 2007 Sub-Investigator for >100 clinical trials (phase 1, 2 e 3 and translational research)

Publications:

1. Martelli O, Garassino M, Sacchetta S, Caristo R, **Zivi A**, Cerbone L and Mancuso A, Darbepoetin alfa administered every three weeks (q3w) in anemic cancer patients receiving chemotherapy (CT), *Anticancer Res.* 2008 May-Jun;28(3B):1767-71
2. Bianchini D, **Zivi A**, Sandhu S and de Bono JS, Horizon scanning for novel therapeutics for the treatment of prostate cancer, *Ann Oncol* 2010 Oct;21 Suppl 7:vii43-vii55
3. Mancuso A, Sacchetta S, Saletti PC, Tronconi C, Milesi L, Garassino M, Martelli O, Leone A, **Zivi A**, Cerbone L, Recine F, Sollami R, Labianca R, Cavalli F, Sternberg CN, Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: results of an Italian/Swiss multicenter survey, *Anticancer Res*, 2010 Oct;30(10):4289-95
4. **Zivi A**, Massard C, De-Bono J, Changing therapeutic paradigms in castrate-resistant prostate cancer, *Clin Genitourin Cancer*, 2010 Dec 1;8(1):17-22

5. Longo F, De Filippis L, **Zivi A**, Vitolo D, Del Signore E, Gori B, Diso D, Anile M, Venuta F, De Giacomo T, Coloni CF, Efficacy and tolerability of long-acting Octreotide in the treatment of thymic tumors: results of a pilot trial, *Am J Clin Oncol*, 2012 Apr;35(2):105-9
6. Attard G, Crespo M, Lim AC, Pope L, **Zivi A**, de Bono JS. Reporting the capture efficiency of a filter-based microdevice: a CTC is not a CTC unless it is CD45 negative -- Letter, *Clin Cancer Res*, 2011 May 1;17(9):3048-9
7. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, **Zivi A**, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM and Scher HI; COU-AA-301 Investigators, Abiraterone and increased survival in metastatic prostate cancer, *N Engl J Med* 2011 May 26;364(21):1995-2005.
8. Yap TA, **Zivi A**, Omlin A, de Bono JS The changing therapeutic landscape of castration-resistant prostate cancer, *Nat Rev Clin Oncol* 2011 Aug 9;8(10): 597-610.
9. de Bono JS, Bianchini D, **Zivi A**, Abiraterone and Increased Survival in Metastatic Prostate Cancer, Correspondence, *N Engl J Med* 2011 Aug 25, 365(8):766-768
10. Mancuso A, Di Paola ED, Leone A, Catalano A, Calabrò F, Cerbone L, **Zivi A**, Messina C, Alonso S, Vigna L, Caristo R, Sternberg CN, Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment, *BJU Int*. 2012 Jan; 109(2):200-6.
11. **Zivi A**, Cerbone L, Recine F, Sternberg CN, Safety and tolerability of pazopanib in the treatment of renal cell carcinoma, *Expert Opin Drug Saf* 2012 Sep;11(5):851-9
12. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators - Collaborators: **Zivi A et al**, Increased survival with enzalutamide in prostate cancer after chemotherapy, *N Engl J Med* 2012 Sep 27;367(13):1187-97
13. Mezynski J, Pezaro C, Bianchini D, **Zivi A**, Sandhu S, Thompson E, Hunt J, Sheridan E, Baikady B, Sarvadikar A, Maier G, Reid AHM, Mulick Cassidy A, Olmos D, Attard G, de Bono JS, Antitumor activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? *Ann Oncol* 2012; Nov;23(11):2943-7
14. Bianchini D, Omlin A, Pezaro C, Lorente D, Ferraldeschi R, Mukherji D, Crespo M, Figueiredo I, Miranda S, Riisnaes R, **Zivi A**, Buchbinder A, Rathkopf DE, Attard G, Scher HI, de Bono J, Danila DC, First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer, *Br J Cancer* 2013 Nov 12;109(10):2579-86
15. Bianchini D, Lorente D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R, **Zivi A**, Attard G, Chowdhury S, de Bono JS, Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone, *Eur J Cancer* 2014 Jan;50(1):78-84
16. Lorente D, Bianchini D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R, **Zivi A**, Attard G, Chowdhury S, De Bono JS, Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer, *Eur J Cancer*. 2014 Mar;50(5):1042-3
17. Blagden S, Omlin A, Josephs DH, Stavraka C, **Zivi A**, Pinato DJ, Anthoney DA, Decordova S, Swales K, Riisnaes R, Pope L, Noguchi K, Shiokawa R, Inatani M, Prince J, Jones K, Twelves CJ, Spicer JF, Banerji U, First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics and pharmacodynamics, in patients with metastatic cancer, *Clin Cancer Res* 2014 Dec 1;20(23):5908-17. Erratum in: *Clin Cancer Res*. 2015 Feb 1;21(3):660. Olmin, Aurelius [corrected to Omlin, Aurelius].
18. Omlin A, Jones RJ, van der Noll R, Satoh T, Niwakawa M, Smith SA, Graham J, Ong M, Finkelman RD, Schellens JH, **Zivi A**, Crespo M, Riisnaes R, Nava-Rodrigues D, Malone MD, Dive C, Sloane R, Moore D, Alumkal JJ, Dymond A, Dickinson PA, Ranson M, Clack G, de Bono J, Elliott T, AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies, *Invest New Drugs*, 2015 Jun;33(3):679-90.

19. Khan KH, Yap TA, Ring A, Molife LR, Bodla S, Thomas K, **Zivi A**, Smith A, Judson I, Banerji U, de Bono JS, Kaye SB, Phase I trial outcomes in older patients with advanced solid tumours, *Br J Cancer*. 2016 Feb 2;114(3):262-8
20. Perez-Lopez R, Lorente D, Blackledge MD, Collins DJ, Mateo J, Bianchini D, Omlin A, **Zivi A**, Leach MO, de Bono JS, Koh DM, Tunariu N, Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer, *Radiology*. 2016 Jul;280(1):151-60.
21. Metcalf GA, Shibakawa A, Patel H, Sita-Lumsden A, **Zivi A**, Rama N, Bevan CL, Ladame S, Amplification-Free Detection of Circulating microRNA Biomarkers from Body Fluids Based on Fluorogenic Oligonucleotide-Templated Reaction between Engineered Peptide Nucleic Acid Probes: Application to Prostate Cancer Diagnosis, *Anal Chem*, 2016 Aug 16;88(16):8091-8
22. Maruzzo M, Basso U, Borsatti E, Evangelista L, Alongi F, Caffo O, Maines F, Galuppo S, De Vivo R, Zustovich F, Palleschi D, **Zivi A**, Sava T, Sorarù M, Iacovelli R, Nicodemo M, Baier S, Fratino L, Zagonel V, Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration-resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region, *Clin Genitourin Cancer*, 2019 Feb;17(1):e187-e194.
23. Dittadi R, Polesello V, **Zivi A**, Carraro P, Evaluation of the possible interference of abiraterone therapy on testosterone immunoassay, *Clin Chem Lab Med*, 2019 Sep 25;57(10):e253-e254
24. Rescigno P, Dolling D, Conteduca V, Rediti M, Bianchini D, Lolli C, Ong M, Li H, Omlin AG, Schmid S, Caffo O, **Zivi A**, Pezaro CJ, Morley C, Olmos D, Romero-Laorden N, Castro E, Saez MI, Mehra N, Smeenk S, Sideris S, Gil T, Banks P, Sandhu SK, Sternberg CN, De Giorgi U, De Bono JS, Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis, *Eur Urol Oncol*. 2020 Apr;3(2):176-182
25. Ottaviano M, Curvietto M, Rescigno P, Tortora M, Palmieri G, Giannarelli D, Aieta M, Assalone P, Attademo L, Avallone A, Bloise F, Bosso D, Borzillo V, Buono G, Calderoni G, Caputo F, Carteni G, Cavallero D, Cavo A, Ciardiello F, Conca R, Conteduca V, De Falco S, De Felice M, De Laurentiis M, De Placido P, De Placido S, De Santo I, De Stefano A, Della Corte CM, Di Franco R, Di Lauro V, Fabbrocini A, Federico P, Festino L, Giordano P, Giuliano M, Gridelli C, Grimaldi AM, Lia M, Marretta AL, Massa V, Mennitto A, Merler S, Merz V, Messina C, Messina M, Milano M, Minisini AM, Montesarchio V, Morabito A, Morgillo F, Mucci B, Nappi L, Napolitano F, Paciolla I, Pagliuca M, Palmieri G, Parola S, Pepe S, Petrillo A, Piantedosi F, Piccin L, Picozzi F, Pietroluongo E, Pignata S, Prati V, Riccio V, Rosanova M, Rossi A, Russo A, Salati M, Santabarbara G, Sbrana A, Simeone E, Silvestri A, Spada M, Tarantino P, Taveggia P, Tomei F, Vincenzo T, Trapani D, Trojanello C, Vanella V, Vari S, Ventriglia J, Vitale MG, Vitiello F, Vivaldi C, von Arx C, Zacchi F, Zampiva I, **Zivi A**, Daniele B, Ascierto PA; SCITO (Società Campana di ImmunoTerapia Oncologica), Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists, *J Immunother Cancer*, 2020 Oct;8(2):e001154
26. Schmid S, Omlin A, Higano C, Sweeney C, Martinez Chanza N, Mehra N, Kuppen MCP, Beltran H, Conteduca V, Vargas Pivato de Almeida D, Cotait Maluf F, Oh WK, Tsao CK, Sartor O, Ledet E, Di Lorenzo G, Yip SM, Chi KN, Bianchini D, De Giorgi U, Hansen AR, Beer TM, Pernelle L, Morales-Barrera R, Tucci M, Castro E, Karalis K, Bergman AM, Le ML, Zürcher-Härdi U, Pezaro C, Suzuki H, **Zivi A**, Klingbiel D, Schär S, Gillessen S, Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations, *JAMA Netw Open*, 2020 Oct 1;3(10):e2021692
27. Maruzzo M, Verzoni E, Vitale MG, Dionese M, Buti S, Galli L, **Zivi A**, Watutantrige-Fernando S, Zielli T, Zanardi E, Sabbatini R, Basso U, Zagone V, Procopio G, Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14), *Front Oncol*, Front. Oncol., 25 November 2021
28. Brunelli M, Tafuri A, Cima L, Cerruto MA, Milella M, **Zivi A**, Buti S, Bersanelli M, Fornarini G, Vellone VG, Rebuzzi SE, Procopio G, Verzoni E, Bracarda S, Sabbatini R, Baldessari C, Eccher A, Passalacqua R, Perrucci B, Giganti MO, Donini M, Panni S, Tucci M, Prati V, Ortega C, Calò A, Alongi F, Munari E,

Pappagallo G, Iacovelli R, Mosca A, Porta C, Martignoni G, Antonelli A, MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma, *J Clin Pathol* 2022 Jan;75(1):39-44

Abstracts and posters:

1. Longo F, Proietti E, Raimondi C, Graziano V, **Zivi A**, Sacco P, Cerbone L, Russillo M, Restuccia M & di Seri M, Treatment of elderly patients with metastatic colorectal cancer (MCRC): our experience, *Ann Oncol*, 17 (Supplement 6), vi74, June 2006
2. Proietti E, Longo F, Ricciardi S, Tomao S, Graziano V, Raimondi C, **Zivi A**, Recine F, Spalletta B & Di Seri M, Incidence of anaemia and outcome colorectal cancer (CRC) patients: our experience, *Ann Oncol*, Supplement 11:xi44 (24), Nov 2006.
3. **Zivi A**, Di Seri M, Rossi L, Graziano V, Tomao S, Proietti E, Cerbone L, Russillo M, Sacco PC and Longo F, Single institution experience in treatment of elderly patients with metastatic colorectal cancer (MCRC), *Ann Oncol*, Supplement 11: xi46 (32), Nov 2006.
4. Rosati MS, Graziano V, **Zivi A**, Rossi L, Proietti E, Messina CGM, M. Russillo M, Cerbone L, Tomao S and Di Seri M, Venous thromboembolism and cancer, *Annals of Oncology*, Supplement 11: xi67 (H11), Nov 2006.
5. Proietti E, Cerbone L, **Zivi A**, Rosati MS, Restuccia MR, Ricciardi S, Raimondi C, Longo F and Di Seri M, Can anemia influence the outcome in colorectal cancer patients on chemotherapy?, *Annals of Oncology*, Suppl 7: vii84, P-0208, June 2007.
6. Messina CG, Longo F, Di Seri M, Restuccia R, **Zivi A**, Proietti E, Russillo M, Cerbone L, Bianco L, Speranza I, Basile GML and De Filippis L, Capecitabine (X) in elderly patients (pts) with hormone-refractory metastatic breast cancer (MBC), *J Clin Oncol*, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition), Vol 25, No 18S (June 20 Supplement), 2007: 1080
7. Di Seri M, Russillo M, Proietti E, Ricciardi S, **Zivi A**, Tedeschi M, Fulvi A, Gori B and Longo F, Timing of chemo-radiation therapy in the rectal cancer management, *Annals of Oncology*, Suppl 11: xi14 (A59), October 2007.
8. Mancuso A, Leone A, Cerbone L, **Zivi A**, Squilloni E, Bertagnolio F, Caristo R, Gasbarra R, Roberto R and Sternberg CN, Role of EGFR, DCC and k-ras mutations in metastatic colorectal cancer (MCRC) patients treated with Cetuximab, *Annals of Oncology*, Suppl 3: iii39 (F02), May 2008
9. De Sanctis R, Longo F, Gori B, **Zivi A**, Del Signore E, Proietti E, De Filippis L, Stumbo L, Quadrini S, Di Seri M, Safety and efficacy of Bevacizumab with first-line FOLFIRI for metastatic colorectal cancer: single center experience, *Annals of Oncology* 19 (Supplement 8): viii125–viii152, Oct 2008
10. Gori B, **Zivi A**, Falbo T, Recine F, Sollami R, Tedeschi M, Stumbo L, Delli Vneri A, Speranza I, Longo F and Di Seri M, Docetaxel in combination with Gemcitabine as second line treatment in patients with platinum resistant advanced NSCLC, *Annals of Oncology*, 19 (Supplement 9): ix24–ix32, Oct 2008
11. Del Signore E, **Zivi A**, Cerbone L, Recine F, Raimondi C, De Sanctis R, Quadrini S, Grassi P, Basile ML, Minisola S, Fassino V, Longo F, Di Seri M, Zoledronic acid (ZA) and treatment of bone metastasis in patients with advanced lung cancer (NSCLC and SCLC), *Annals of Oncology* 19 (Supplement 9): ix33–ix43, Oct 2008
12. Donato Di Paola E, Alonso S, D'Alessio A, Giuliani R, Calabrò F, Messina C, **Zivi A**, Squilloni E, De Marco S and Sternberg CN, Dose finding study of the combination of satraplatin and gemcitabine in patients with advanced solid tumors, *J Clin Oncol*, 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition), Vol 27, No 15S (May 20 Supplement), 2009: e13534
13. Mancuso P A, Donato De Paola E, Catalano A, Calabrò F, Messina C, **Zivi A**, Cerbone L, Vigna L, Caristo R and Sternberg CN, Phase II dose escalation study of sorafenib in patients with metastatic renal cell carcinoma (mRCC) who have had prior treatment with VEGFR-TKI antiangiogenic treatment, *J Clin Oncol*, 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition), Vol 27, No 15S (May 20 Supplement), 2009: e16027
14. Bianchini D, **Zivi A**, Sandu S, Attard G, Read A, Molife R, Fong P, Olmos D, Oomen NB, Massard C, Hunt J, Thompson E, Parker C, Dearnaley D, De Bono JS, Long-term safety and tolerability of

- abiraterone acetate (AA) in advanced castration resistant prostate cancer (CRPC), Program/Abstract book, P004, 2009 European Multidisciplinary meeting on Urological Cancer, Nov 27-29, 2009; Barcelona, Spain
15. Zivi A, Bianchini D, Sandhu S, Attard G, Reid A, Hunt J, Thompson E, Parker C, Dearnaley D and de Bono J, Durable disease control and safety and tolerability of Abiraterone Acetate (AA) in advanced castration resistant prostate cancer (CRPC), *Proceedings*, 2010 Genitourinary Cancer Symposium, Mar 5-7, 2010; San Francisco, California
 16. Bianchini D, Zivi A, Attard G, Mezynski J, Cassidy A, Sandhu S, Hunt J, Sheridan L, Thompson E, de Bono JS, Weight change analysis in advanced castration resistant prostate cancer (CRPC) patients treated with Abiraterone Acetate (AA) single agent and in combination with steroids, *Critical Reviews in Oncology/Hematology*, May 2011, Vol. 78 Issue: Number 4 pS23
 17. Mezynski, J, Attard G, Zivi A, Bianchini D, Sandhu S, Cassidy A, Mulick, Thompson E, Reid A, Baikady B, de Bono JS, Evaluating the antitumour activity of docetaxel following treatment with abiraterone acetate and steroids: evidence for cross-resistance, *Critical Reviews in Oncology/Hematology*, May 2011, Vol. 78 Issue: Number 4 pS23-S24
 18. Olmos D, Clark J, Brewer D, Barwell L, Attard G, Reid AH, Sandhu SK, Zivi A, Bianchini D, Babu Oomen N, Thompson E, Molife LR, Kaye SB, Parker C, Cooper C, Jones RJ, De Bono JS, An evaluation of blood mRNA expression array signatures derived from unsupervised analyses in the identification of prostate cancers with poor outcome, *J Clin Oncol*, 2011 ASCO Annual Meeting Proceedings (Post-Meeting Edition), Vol 29, No 15_suppl (May 20 Supplement), 2011: 4577
 19. Mukherji D, Pezaro CJ, Bianchini D, Zivi A and De Bono JS, Response to abiraterone acetate in the postchemotherapy setting in patients with castration-resistant prostate cancer whose disease progresses early on docetaxel, *J Clin Oncol*, 2012 Genitourinary Cancers Symposium; Vol 30, No 5_suppl (February 10 Supplement), 2012: 17
 20. Bianchini D, Reid A, Attard G, de Bono J, Sandhu S, Cassidy Mulick A, Mukherji D, Pezaro C, Zivi A, Omlin A, Sarvadikar A and Thompson E, Abstract C9: Treatment response to abiraterone acetate (AA) in patients with castration-resistant prostate cancer (CRPC) based on circulating tumor cells (CTCs), prostate-specific antigen (PSA), and imaging, *Cancer Res* February 6, 2012 72; C9.
 21. Bianchini D, Sandhu SK, Cassidy AM, Zivi A, Mezynski J, Mukherji D, Pezaro CJ, Reid AH, Oommen NB, Olmos D, Omlin AG, Sarvadikar A, Thompson E, Hunt J, Sheridan E, Attard G, De Bono JS, Durable radiologic and clinical disease stability beyond PSA progression in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA), *J Clin Oncol* 30, 2012 (suppl; abstr 4553)
 22. Zivi A, Bianchini D, Sandhu SK, Cassidy AM, Mezynski J, Mukherji D, Pezaro CJ, Reid AH, Oommen NB, Olmos D, Omlin AG, Sarvadikar A, Arogundade J, Thompson E, Hunt J, Sheridan E, Attard G, De Bono JS, Durable radiologic and clinical disease stability beyond PSA progression in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with Abiraterone Acetate (AA), *Tumori*, Vol 13, no3, S141 - F7, Oct 2012.
 23. Banerji U, Ranson M, Schellens JHM, Esaki T, Dean E, Zivi A, Van der Noll R, Stockman PK, Marotti M, Garrett MD, Davies BR, Elvin P, Hastie A, Lawrence P, Cheung SYA, Stephens C, Tamura C, Results of two phase I multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: Biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors, *Proceedings of the 104th Annual Meeting of the American Association for Cancer Research*; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; 2013, Abstract nr LB-66
 24. Bianchini D, Omlin AG, Pezaro CJ, Mukherji D, Lorente Estelles D, Zivi A, Ferraldeschi R, Crespo M, Buchbinder A, Attard G, Scher HI, De Bono JS, Danila DC, First-in-human phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide (LNA-ASO) to androgen receptor (AR) mRNA in patients with castration-resistant prostate cancer (CRPC), *J Clin Oncol* 31, 2013 (suppl; abstr 5052)
 25. Mateo J, De Bono JS, Ramanathan RK, Lustberg MB, Zivi A, Basset D, Ng M, Young A-M, Garrett M, Decordova S, Raynaud FI, Yap TA, Zukiwski AA, Proniuk S, Shapiro CL, A first-in-human phase I trial of AR-12, a PDK-1 inhibitor, in patients with advanced solid tumors, *J Clin Oncol* 31, 2013 (suppl; abstr 2608)

26. Omlin AG, Jones RJ, van der Noll R, Graham J, Ong M, Finkelman RD, Schellens JHM, Zivi A, Crespo M, Clack G, Alumkal JJ, Dymond A, Dickinson A, Ranson M, Malone MD, De Bono JS, Elliott T, A first-in-human study of the oral selective androgen receptor down-regulating drug (SARD) AZD3514 in patients with castration-resistant prostate cancer (CRPC), *J Clin Oncol* 31, 2013 (suppl; abstr 4511)
27. Khan KH, Molife LR, Bodla S, Zivi A, Smith A, Ang J, Judson I, Banerji U, De Bono JS and Kaye SB, Phase I trials in patients (pts) >65 years with advanced solid cancers: Do they fare worse than younger patients?, *Eur J Cancer* 49, 2013 (Suppl 2, S345 Po1576)
28. Capelan M, Kumar P, Tolcher AW, Zivi A, Desai M, Papadopoulos KP, Senaldi G, Patnaik A, Banerji U, Rasco DD, A first-in-human Phase I study of DS-3078a, an oral TORC1/2 inhibitor, in patients with advanced solid tumors: Preliminary results, *Mol Cancer Ther* 2013;12(11 Suppl):C173.
29. Alken SP, Rihawi K, Michalarea V, Zivi A, Bodla S, Greenwood K, Kaye SB, Banerji U, De Bono JS, Saran F, Molife LR, Primary malignant brain tumours (PMBT) in phase I studies: Barriers to treatment and patient outcomes, *J Clin Oncol* 32:5s, 2014 (suppl; abstr 2024)
30. Banerji U, Smith AD, Zivi A, Lorente D, Rihawi K, Tunariu N, Stewart A, Thavasu P, Kaag A, Radhakrishnan R, Maacke H, Molife LR, Kaye SB, De Bono JS, Dual targeting of RAF-MEK-ERK and PI3K-AKT-mTOR pathways in RAS-mutant cancers: Preclinical insights and institutional experience from a clinical trial of binimetinib (MEK162) plus BYL719, *J Clin Oncol* 32, 2014 (suppl; abstr e13559)
31. Roberg Sita-Lumsden A, Leach D, Zivi A, Waxman J, Winkler M, Bevan C, A circulating miRNA signature to help prognosticate at prostate cancer diagnosis, *J Clin Oncol* 35, 2017 (suppl 6S; abstract 108)
32. Roberg Sita-Lumsden A, Leach D, Zivi A, Winkler M, Waxman J, Bevan C, A signature of miRNAs in the blood to help prognosticate prostate cancer at the time of diagnosis, *J Clin Oncol* 35, 2017 (suppl; abstr e16558)
33. Roberg Sita-Lumsden A, Leach D, Waxman J, Winkler M, Bevan C, Zivi A, A circulating miRNA signature to better stratify prostate cancer patients at diagnosis, *Annals Oncol*, Vol 28, 1 Oct 2017 Issue (suppl_6, Abstr B15)
34. Rescigno P, Dolling D, Rediti M, Conteduca V, Ong M, Li H, Omlin AG, Schmid S, Caffo O, Zivi A, Pezaro CJ, Morley C, Romero-Laorden N, Saez MI, Mehra N, Sideris S, Sandhu SK, Sternberg CN, De Giorgi U, De Bono JS, Early changes in PSA and association with outcomes in mCRPC patients, *J Clin Oncol* 36, 2018 (suppl; abstr 5063)
35. Maruzzo M, Verzoni E, Pierantoni F, Galli L, Vignani F, Buti S, Pignata S, Zanardi E, Sbrana A, Procopio G, Zivi A, Zielli T, Mini E, Roviello G, Basso U, Zagonel V, Prognostic role of T3/T4 ratio in metastatic renal cell carcinoma (mRCC): Preliminary results of the threeFOUR multicenter study (Meet-Uro 14), *J Clin Oncol* 38: 2020 (suppl; abstr e17093)
36. Maruzzo M, Bortolami A, Palleschi D, Zivi A, Nicodemo M, Sartori D, De Vivo R, Zustovich F, Bimbatti D, Pastorelli D, Vultaggio GD, Sorarù M, Ballestrin M, Zanchetta G, Modonesi C, Randisi P, Barile C, Perri G, Basso U, Zagonel V, Use of nivolumab (N) and cabozantinib (C) for treatment of the metastatic renal cell carcinoma (mRCC) in the Veneto region: Results of AMOUR study, *J Clin Oncol* 39, 2021 (suppl 6; abstr 290)

Editorial activity

Sep/2017 Journal of Cancer Clinics, Editorial board Member
 Feb/2018 Annals of Clinical Images, Editorial board Member
 Mar/2018 Oncogen, Editorial Board Member
 Aug/2018 Current Trends in Radiation Oncology and Cancer, Editorial board Member
 Aug/2018 Journal of Reconstructive Surgery & Anaplastology, Editorial board Member
 Aug/2018 Universal Journal of Oncology, Editorial Board Member

Invited lectures/Chair:

11/Jul/2008 ASCO 2008 highlights on Head and Neck cancer, Sarcomas and Brain Tumors,

	VII Corso Educazionale AIOM Giovani – Sezione Regione Lazio “ASCO 2008: Le novità”, Rome
11/Nov/2008	Proposta di ricerca su linea cellulare, <u>Vie alternative e misconosciute degli anti-EGFR Mab e Multitargets TKI per il trattamento delle neoplasie solide: teoria e proposte pratiche</u> , Rome
16-20/Apr/2010	New approaches to hormonal therapy, <u>25th Anniversary EAU Congress</u> , Barcelona
28/Apr/2014	Valutazione critica degli studi clinici di registrazione di Abiraterone e Cabazitaxel, <u>Trattamento del carcinoma prostatico avanzato</u> , Bolzano
20/Nov/2014	Diversi TKi, stesse tossicità?, <u>Prospettive nel trattamento del carcinoma renale metastatico</u> , Bolzano
08/Apr/2017	Il trattamento della malattia resistente alla castrazione <u>Aggiornamenti in tema di neoplasia prostatica</u> , Mestre
12/Mar/2018	Trattamento multidisciplinare integrato del carcinoma della prostata metastatico: valutazione del ruolo della targeted alpha therapy (tat) – trive-tat Chair, Padova
20/Sep/2018	Evoluzione dell’algoritmo terapeutico nel paziente con carcinoma renale metastatico in seconda linea <u>Tavola rotonda – presentazione ed esperienza clinica nel triveneto</u> , Padova
29/Nov/2018	Proposta di PDTA per pazienti affetti da tumore della vescica Il sessione Malattia muscolo-invasiva <u>Chemioterapia adiuvante</u> , Padova
03/Jun/2019	Updating nel trattamento del tumore renale metastatico: opinioni a confronto Parte 2: aspetti terapeutici <u>Antiangiogenesi, immunoterapia o entrambe? and Chair</u>

Teaching

18/Sep/2013	Teaching session for Foundation Year 1 Doctors <u>Acute Oncological Emergencies</u> Imperial College Healthcare NHS Trust , London
From 2018	Teaching sessions School of Medicine and Medical Oncology School Genito-urinary cancers Università degli studi di Verona, Verona

Languages spoken

Italian: mother tongue
English: fluent

Contacts

Email: [REDACTED]
andrea.zivi@aovr.veneto.it
[REDACTED]

Date, 15/Mar/2022

Dr Andrea Zivi

